Goldman Sachs Raises Accenture Price Target to $260 From $230

Susquehanna raised its price target for Accenture to $210 from $153. Separately, Goldman Sachs increased its target to $260 from $230. Accenture's stock has seen recent gains.

Accenture (ACN) shares rose 21% after Q4 earnings of $3.29 per share beat estimates by $0.11. Revenue grew 6.3% YoY to $18.7B, exceeding forecasts. The company offered optimistic guidance for 2027, with revenue growth projected between 3% and 6%. Accenture's dividend yield is 2.96% with a payout ratio of 47%, and it has a GF Score of 87, indicating strong financial health.

Accenture (ACN) shares rose 18.5% after Q4 earnings beat expectations, with EPS up 9% and revenue up 6% to $18.7B. The company's dividend yield is 2.96%, and it has a GF Value of $359.69, suggesting undervaluation. Insider sales totaled $1.72M in the last three months.

Accenture rose 18% after Q4 revenue of $18.7B beat estimates. McCormick's Q3 results topped expectations but shares fell 2% amid Unilever's acquisition. McKesson gained 4% on reaffirmed guidance and a CVS Health partnership. United Therapeutics climbed 6% after a court ruling, while Liquidia dropped 15%. Constellation Energy gained 3% on a 20-year Amazon deal. Synopsys jumped 8% with 2027 revenue targets. Sigma Lithium slid 16% after halting production.

Accenture (ACN) shares rose 18% after Q4 revenue of $18.68B and EPS of $3.29 beat estimates, easing AI disruption fears. New bookings reached $22.17B. Guidance for FY2027 was in line with consensus. Peers IBM, Cognizant, and Wipro also gained.

Accenture (ACN) shares rose 21% after Q4 earnings beat estimates and FY27 revenue guidance was raised. The Dow, S&P 500, and Nasdaq all declined. Treasury yields hit multi-year highs, with the 10-year yield at 5.34%. U.S. Manufacturing PMI slipped to 54.5 in September, marking nine months of expansion.